Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
Background:. Antiviral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant (IT) phase. We compared the outcomes between the untreated IT phase and the treated immune-active (IA) phase in noncirrhotic HBeAg-positive CHB patients. Methods:. We systematically sea...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2023-02-01
|
| Series: | Hepatology Communications |
| Online Access: | http://journals.lww.com/10.1097/HC9.0000000000000011 |
| _version_ | 1828000644514971648 |
|---|---|
| author | Han Ah Lee Seung Up Kim Yeon Seok Seo Sang Hoon Ahn Chai Hong Rim |
| author_facet | Han Ah Lee Seung Up Kim Yeon Seok Seo Sang Hoon Ahn Chai Hong Rim |
| author_sort | Han Ah Lee |
| collection | DOAJ |
| description | Background:. Antiviral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant (IT) phase. We compared the outcomes between the untreated IT phase and the treated immune-active (IA) phase in noncirrhotic HBeAg-positive CHB patients.
Methods:. We systematically searched 4 databases, including PubMed, Medline, Embase, and Cochrane, until August 2021. The pooled incidence rates of HCC and mortality in the IT and IA cohorts and phase change in the IT cohort were investigated. Studies that included patients with liver cirrhosis were excluded.
Results:. Thirteen studies involving 11,903 patients were included. The overall median of the median follow-up period was 62.4 months. The pooled 5-year and 10-year incidence rates of HCC were statistically similar between the IT and IA cohorts (1.1%, 95% CI: 0.4%–2.8% vs. 1.1%, 95% CI: 0.5%–2.3%, and 2.7%, 95% CI: 1.0%–7.3% vs. 3.6%, 95% CI: 2.4%–5.5%, respectively, all p>0.05). The pooled 5-year odds ratio of HCC between IT and IA cohorts was 1.05 (95% CI: 0.32–3.45; p=0.941). The pooled 5-year incidence rate of mortality was statistically similar between the IT and IA cohorts (1.9%, 95% CI: 1.1%–3.4% vs. 1.0%, 95% CI: 0.3%–2.9%, p=0.285). Finally, the pooled 5-year incidence rate of phase change in the IT cohort was 36.1% (95% CI: 29.5%–43.2%).
Conclusion:. The pooled incidence rates of HCC and mortality were comparable between the untreated IT and the treated IA phases in noncirrhotic HBeAg-positive CHB patients. |
| first_indexed | 2024-04-10T06:17:31Z |
| format | Article |
| id | doaj.art-91b690cab1ff49fca12524708fb4aa8b |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-04-10T06:17:31Z |
| publishDate | 2023-02-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-91b690cab1ff49fca12524708fb4aa8b2023-03-02T06:30:44ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2023-02-0172e0011e001110.1097/HC9.0000000000000011HC90000000000000011Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysisHan Ah Lee0Seung Up Kim1Yeon Seok Seo2Sang Hoon Ahn3Chai Hong Rim4 1 Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea 2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 4 Departments of Internal Medicine, Korea University College of Medicine, Seoul, Korea 2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 5 Department of Radiation Oncology, Korea University College of Medicine, Seoul, KoreaBackground:. Antiviral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant (IT) phase. We compared the outcomes between the untreated IT phase and the treated immune-active (IA) phase in noncirrhotic HBeAg-positive CHB patients. Methods:. We systematically searched 4 databases, including PubMed, Medline, Embase, and Cochrane, until August 2021. The pooled incidence rates of HCC and mortality in the IT and IA cohorts and phase change in the IT cohort were investigated. Studies that included patients with liver cirrhosis were excluded. Results:. Thirteen studies involving 11,903 patients were included. The overall median of the median follow-up period was 62.4 months. The pooled 5-year and 10-year incidence rates of HCC were statistically similar between the IT and IA cohorts (1.1%, 95% CI: 0.4%–2.8% vs. 1.1%, 95% CI: 0.5%–2.3%, and 2.7%, 95% CI: 1.0%–7.3% vs. 3.6%, 95% CI: 2.4%–5.5%, respectively, all p>0.05). The pooled 5-year odds ratio of HCC between IT and IA cohorts was 1.05 (95% CI: 0.32–3.45; p=0.941). The pooled 5-year incidence rate of mortality was statistically similar between the IT and IA cohorts (1.9%, 95% CI: 1.1%–3.4% vs. 1.0%, 95% CI: 0.3%–2.9%, p=0.285). Finally, the pooled 5-year incidence rate of phase change in the IT cohort was 36.1% (95% CI: 29.5%–43.2%). Conclusion:. The pooled incidence rates of HCC and mortality were comparable between the untreated IT and the treated IA phases in noncirrhotic HBeAg-positive CHB patients.http://journals.lww.com/10.1097/HC9.0000000000000011 |
| spellingShingle | Han Ah Lee Seung Up Kim Yeon Seok Seo Sang Hoon Ahn Chai Hong Rim Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis Hepatology Communications |
| title | Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis |
| title_full | Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis |
| title_fullStr | Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis |
| title_full_unstemmed | Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis |
| title_short | Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis |
| title_sort | comparable outcomes between immune tolerant and active phases in noncirrhotic chronic hepatitis b a meta analysis |
| url | http://journals.lww.com/10.1097/HC9.0000000000000011 |
| work_keys_str_mv | AT hanahlee comparableoutcomesbetweenimmunetolerantandactivephasesinnoncirrhoticchronichepatitisbametaanalysis AT seungupkim comparableoutcomesbetweenimmunetolerantandactivephasesinnoncirrhoticchronichepatitisbametaanalysis AT yeonseokseo comparableoutcomesbetweenimmunetolerantandactivephasesinnoncirrhoticchronichepatitisbametaanalysis AT sanghoonahn comparableoutcomesbetweenimmunetolerantandactivephasesinnoncirrhoticchronichepatitisbametaanalysis AT chaihongrim comparableoutcomesbetweenimmunetolerantandactivephasesinnoncirrhoticchronichepatitisbametaanalysis |